
S&P TEST

SWOT & PESTLE.com

HIKMA PHARMACEUTICALS PLC SWOT & PESTLE ANALYSIS

© Barakaat Consulting - An Ezzy IT Consulting Business

This is a licensed product and is not to be photocopied or distributed. All rights reserved. Unauthorized reproduction is strictly prohibited. Research is based on best available materials and resources. To purchase reprints of this document, please email support@swotandpestle.com.

Company Name : Hikma Pharmaceuticals plc

Company Sector : Pharmaceuticals

Operating Geography : United Kingdom, Europe, Global

About the Company :

Hikma Pharmaceuticals plc is a non-branded generic and in-licensed pharmaceutical company headquartered in London, United Kingdom. In 1978, Samih Darwazah founded the company in Amman, Jordan. The company has 29 manufacturing facilities spread across 11 countries: the United States, Portugal, Italy, Jordan, Saudi Arabia, Algeria, Germany, Egypt, Morocco, Tunisia, and Sudan. It undertakes research and development in the areas such as cardiology, anti-infective, neurology, and dermatology. In the MENA region, Hikma's branded business segment consists of the development and sale of branded generics and in-licensed patented products. It offers 499 different medications in 1,256 different dosage strengths. Actos, Amoclan, Blopress, Omnicef, Prograf, and Suprax are some of the most popular products. Argatroban, fentanyl, phenylephrine, Robaxin, and iron gluconate are among the speciality injectable medications sold by Hikma in the United States, Europe, and MENA. As of early 2023, Hikma employed over 8,700 people.

Hikma Pharmaceutical's USP lies in its reputation for quality, high brand awareness, and FDA-inspected manufacturing facilities in the United States. The mission statement of Hikma Pharmaceuticals reads, "Improving lives' is Hikma's main mission, through providing high-quality affordable medication to patients and 'Improving lives' of its local communities and its employees".

Revenue :

US\$ 2,553 million - FY ending 31st December 2021

US\$ 2,341 million - FY ending 31st December 2020

SWOT Analysis :

The SWOT Analysis for Hikma Pharmaceuticals plc is given below:

Strengths	Weaknesses
<ul style="list-style-type: none"> 1.Strongly positioned to deliver sustainable growth 2.World-class infrastructure for generics development and manufacturing 3.Manufacturing flexibility can handle fluctuating demand 4.Continuous launch of new drugs 5.One of the largest pharmaceutical brands in MENA 6.Consistently maintained cash flow that supports R&D 	<ul style="list-style-type: none"> 1.Presence in few products categories
Opportunities	Threats
<ul style="list-style-type: none"> 1.High demand for Covid-19 treatment drugs 2.Elective surgery products will see demand post covid 3.Biosimilar received a positive response in US 	<ul style="list-style-type: none"> 1.Emerging innovative sales channels increase competition 2.Reduced supply of APIs is inhibiting production 3.Patent infringement litigation with Amarin pharma

PESTLE Analysis :

The PESTLE Analysis for Hikma Pharmaceuticals plc is given below:

<p style="text-align: center;">Political</p> <p>1.Governments focused on domestication of manufacturing</p> <p>2.Brexit will result into increased operational restrictions</p>	<p style="text-align: center;">Economical</p> <p>1.The global economic downturn has led to higher use of generics</p> <p>2.Hyperinflationary conditions in Middle East will impact growth</p>
<p style="text-align: center;">Social</p> <p>1.Ageing population leads to increased healthcare spending</p>	<p style="text-align: center;">Technological</p> <p>1.Complex generics gaining prominence</p> <p>2.Manufacturing 4.0 to revolutionize drug production</p>
<p style="text-align: center;">Legal</p> <p>1.CFC rules to affect European subsidiaries</p>	<p style="text-align: center;">Environmental</p> <p>1.Streamlined energy and carbon reporting framework will highlight energy usage</p> <p>2.TCFD compliance ensures transparency of climate impact</p>

Please note that our free summary reports contain the SWOT and PESTLE table contents only. The complete report for **Hikma Pharmaceuticals plc** SWOT & PESTLE Analysis is a paid report at **27 U.S.D.**



* By clicking on "Buy Now" you agree to accept our "Terms and Conditions."



S&P

SWOT & PESTLE.com

SWOT & PESTLE.com is a leading strategy research portal covering detailed Strengths, Weaknesses, Opportunities, Threats (SWOT) and Political, Economic, Social, Technological, Legal and Environmental (PESTLE) analysis of leading industry sectors and organizations across the globe. Our full and comprehensive collection on SWOT and PESTLE has been written by our team of professional analysts consisting of MBA's, CFA's and industry experts. Our analysis has helped businesses, researchers and scholars with valuable insights to make strategic decisions and take their research forward.

We at SWOT & PESTLE.com aim to aid the understanding of the multifaceted business world by presenting a list of diverse companies from across the globe. Business organizations today cannot function in ways that ignore the surroundings that they are set in. SWOT & PESTLE.com makes a keen observation into this aspect and accounts for factors affecting such businesses.

Copyright Notice

The information provided in the SWOT and PESTLE research reports on www.swotandpestle.com are from publicly available documents and sources which are deemed reliable. Further the reports contain analysis and views from the SWOT & PESTLE.com research and analyst team which consists of qualified experts. While every attempt has been made to ensure completeness, accuracy and reliability of the analysis, Barakaat Consulting and its associate websites cannot be held responsible or legal liable for omissions or errors in our reports or on any of our pages.

(C)2024 Barakaat Consulting. All rights reserved. This report may not be reproduced, copied or redistributed, in whole or in part, in any form or by any means, without the express written consent of Barakaat Consulting. Also, Barakaat Consulting is the sole copyright owner of this report, and any use of this report by any third party is strictly prohibited without a license expressly granted by Barakaat Consulting. Neither all nor any part of the contents of this report, or any opinions expressed herein, can be used in advertising, press releases, or promotional materials without prior written approval from Barakaat Consulting. Any violation of Barakaat Consultings rights in this report will be executed to the fullest extent of the law, including the pursuit of monetary damages and injunctive relief in the event of any breach of the foregoing restrictions.

Client Support:
support@swotandpestle.com